A minor fraction of GBMs (0.8%, 2/240) contained mutations in both the TERT promoter and IDH1/2 suggesting they were treated oligodendrogliomas that were diagnosed as small cell GBMs. This evidence concerns the gene IDH1 and oligodendroglioma.